Palbociclib, Ribociclib and Abemaciclib, as specific CDK4/6 inhibitors, obtained FDA approval for the treatment of ER-positive metastatic cancers [16], which combined with endocrine agents like fulvestrant and letrozole, may improve survival rates [17]. The gene discussed is CDK4; the disease is metastatic malignant neoplasm.